Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798770 | 0.81 | EDNRA (0.32) | MAPK8TDP1EDNRAALDH1A1 | |
| SCHEMBL1797443 | 0.79 | CMA1 (0.38) | MAPK8POLBCASP6 | |
| SCHEMBL1799870 | 0.77 | NPC1 (0.31) | TDP1 | |
| SCHEMBL1799693 | 0.77 | CTSK (0.36) | MAPK8TDP1 | |
| SCHEMBL1799689 | 0.77 | CTSK (0.36) | MAPK8TDP1 | |
| SCHEMBL2768617 | 0.72 | GRM5 (0.39) | POLBCASP6 | |
| SCHEMBL1795615 | 0.70 | NPC1 (0.30) | — | |
| SCHEMBL1794725 | 0.69 | MAPK8 (0.35) | MAPK8TDP1POLBCASP6EDNRA | |
| SCHEMBL1801475 | 0.68 | CNR2 (0.34) | MAPK8TDP1EDNRAPDE5A | |
| SCHEMBL5018742 | 0.63 | TAAR1 (0.41) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803809-B2 | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | BACE1, APP, BACE2 | MAPK8 4457/4885TDP1 440/4885POLB 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.